Vorinostat (SAHA)
别名: MK0683, Suberoylanilide hydroxamic acid
中文名称:伏立诺他
目录号:S1047 Purity: 99.96%
Vorinostat (SAHA)是一种HDAC抑制剂,无细胞试验中IC50为~10 nM。Vorinostat 会抑制高效的HPV-18 DNA扩增。
CAS: 149647-78-9
客户使用Selleck的Vorinostat (SAHA)发表文献560篇
- Signal Transduct Target Ther, 2023 8(1):11
- Cell Discov, 2023 9(1):85
- Cell Discov, 2023 9(1):29
- Nature, 2022 605(7908):160-165
- Cell, 2020 S0092-8674(20)31394-5
- Cancer Cell, 2020 13;37(4):599-617 e7
- Nat Biotechnol, 2020 10.1038/s41587-019-0388-4
- Mol Cancer, 2020 19(1):4
- Cell, 2019 36(2):179-193
- Cell, 2019 176(1-2):198-212
- Cancer Cell, 2019 36(2):179-193
- Cancer Discov, 2019 9(4):526-545
- Cell, 2018 174(3):536-548.e21
- Cell Host Microbe, 2018 24(5):689-702
- Cell Metab, 2018 5;27(6):1294-1308.e7
- J Hematol Oncol, 2018 11(1):32
- Nature, 2017 551(7679):247-250
- Cell Host Microbe, 2017 21(5):569-579
- Cancer Discov, 2017 7(12):1450-1463
- Ann Oncol, 2016 27(3):508-13
- Cancer Cell, 2016 29(3):311-323
- Nat Med, 2015 21(10):1163-71
- Nat Med, 2015 10.1038/nm.3855
- Nat Biotechnol, 2015 10.1038/nbt.3130
- Cell, 2014 28;158(5):989-999.
- Blood, 2013 123(5):706-16
- Blood, 2013 14;121(11):2038-50
- Blood, 2012 8;120(19):3958-67
- Nature, 2011 471(7337):235-9
- Nat Biotechnol, 2011 29(3):255-65
- Cell Rep, 2024 43(1):113575
- NPJ Precis Oncol, 2024 8(1):52
- Cell Oncol (Dordr), 2024 10.1007/s13402-024-00939-5
- Br J Haematol, 2024 10.1111/bjh.19658
- Clin Epigenetics, 2024 16(1):13
- Int J Mol Sci, 2024 25(17)9241
- Oncotarget, 2024 15:124-133
- Biomedicines, 2024 12(6)1203
- Viruses, 2024 16(5)775
- Eur J Pharm Sci, 2024 197:106767
- Sci Rep, 2024 14(1):25526
- PLoS One, 2024 19(3):e0295096
- PLoS One, 2024 19(7):e0306168
- PLoS One, 2024 19(6):e0304914
- Alcohol Clin Exp Res, 2024 10.1111/acer.15273
- Exp Parasitol, 2024 258:108716
- Cancer Res Commun, 2024 4(2):349-364
- ResearchWorks Archive, 2024
- Nat Commun, 2023 14(1):809
- Nat Commun, 2023 14(1):5362
- Mol Cell, 2023 83(11):1872-1886.e5
- J Clin Invest, 2023 133(18)e166490
- Proc Natl Acad Sci U S A, 2023 120(28):e2219543120
- EMBO Mol Med, 2023 15(3):e16629
- PLoS Biol, 2023 21(4):e3002038
- Cell Death Dis, 2023 14(11):739
- Cell Rep, 2023 42(9):113044
- Cell Rep, 2023 42(9):113098
- JCI Insight, 2023 8(7)e162907
- Front Immunol, 2023 14:1260545
- Cell Death Discov, 2023 9(1):289
- Clin Epigenetics, 2023 15(1):73
- Mol Cancer Ther, 2023 22(1):52-62
- Int J Mol Sci, 2023 24(14)11753
- Int J Mol Sci, 2023 24(10)8719
- Int J Mol Sci, 2023 24(16)12926
- J Virol, 2023 97(10):e0111523
- Am J Cancer Res, 2023 13(12):6241-6255
- Cancers (Basel), 2023 15(14)3650
- Front Oncol, 2023 13:1287444
- Front Oncol, 2023 13:1048419
- Viruses, 2023 15(9)1863
- Cancer Med, 2023 12(8):9815-9825
- Cancer Med, 2023 10.1002/cam4.6021
- PLoS One, 2023 18(2):e0277305
- Gene, 2023 885:147704
- PeerJ, 2023 11:e15659
- bioRxiv, 2023 2023.07.28.551016
- bioRxiv, 2023 2023.12.13.571583
- Nat Commun, 2022 13(1):6226
- Nat Commun, 2022 13(1):107
- Cancer Commun (Lond), 2022 10.1002/cac2.12332
- J Adv Res, 2022 S2090-1232(22)00246-6
- Clin Transl Med, 2022 12(5):e798
- Cell Rep, 2022 41(12):111850
- Cell Rep, 2022 40(12):111396
- JCI Insight, 2022 7(22e158060)
- JCI Insight, 2022 7(23)e160130
- Front Immunol, 2022 13:978800
- Cell Death Discov, 2022 8(1):393
- Cells, 2022 11(15)2380
- iScience, 2022 25(10):105182
- Front Bioeng Biotechnol, 2022 10:855755
- Front Plant Sci, 2022 13:1041095
- Front Pharmacol, 2022 13:797469
- Front Pharmacol, 2022 13:1032975
- Front Cell Dev Biol, 2022 10:909557
- Front Chem, 2022 10:837987
- Pharmaceutics, 2022 14(7)1420
- Oncotarget, 2022 13:1122-1135
- Cancers (Basel), 2022 14(8)1897
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:1048741
- Biomedicines, 2022 10(2)373
- Andrology, 2022 10.1111/andr.13154
- Cell Cycle, 2022 1-13
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Metabolites, 2022 10.3390/metabo12060528
- Med Oncol, 2022 39(10):150
- Proteomics, 2022 e2100372.
- SLAS Discov, 2022 S2472-5552(22)13702-0
- Biochem Biophys Res Commun, 2022 620:29-34
- Cancer Chemother Pharmacol, 2022 89(5):643-653
- Protoplasma, 2022 10.1007/s00709-022-01764-z
- Nanotheranostics, 2022 6(3):325-336
- Nat Commun, 2021 12(1):4404
- Neuro Oncol, 2021 23(3):376-386
- Neuro Oncol, 2021 23(2):226-239
- J Clin Invest, 2021 131(20)e145035
- Adv Sci (Weinh), 2021 e2103360
- Hepatology, 2021 10.1002/hep.32245
- Genome Med, 2021 13(1):189
- Clin Cancer Res, 2021 clincanres.2486.2019
- Cancer Res, 2021 canres.1547.2021
- EBioMedicine, 2021 65:103241
- EBioMedicine, 2021 69:103457
- EMBO Mol Med, 2021 13(8):e13901
- Exp Hematol Oncol, 2021 10(1):19
- J Colloid Interface Sci, 2021 603:319-332
- Cancer Lett, 2021 521:268-280
- Cancer Lett, 2021 512:28-37
- Pharmacol Res, 2021 171:105787
- Sci China Life Sci, 2021 10.1007/s11427-020-1855-4
- Cell Death Dis, 2021 12(6):532
- Oncogene, 2021 10.1038/s41388-021-01931-1
- Elife, 2021 10e65654
- Elife, 2021 10e63810
- Anal Chem, 2021 93(38):12872-12880
- J Pathol, 2021 10.1002/path.5781
- Int J Radiat Oncol Biol Phys, 2021 S0360-3016(21)02625-0
- mBio, 2021 12(6):e0298021
- Cells, 2021 10(5)1001
- Biochem Pharmacol, 2021 188:114546
- Mol Cancer Ther, 2021 20(12):2362-2371
- Int J Mol Sci, 2021 22(9)4559
- J Enzyme Inhib Med Chem, 2021 36(1):34-47
- Int J Mol Sci, 2021 22(7)3621
- Front Cell Dev Biol, 2021 9:682561
- J Virol, 2021 JVI0085321
- Aging (Albany NY), 2021 13(14):17978-18005
- Cancers (Basel), 2021 13(17)4476
- Cancers -Basel), 2021 13(9)2207
- Cancers (Basel), 2021 13(15)3862
- Transl Oncol, 2021 14(10):101181
- Transl Oncol, 2021 14(1):100982
- Front Oncol, 2021 11:723966
- Front Oncol, 2021 11:773186
- Ann Transl Med, 2021 9(18):1455
- J Dermatol Sci, 2021 S0923-1811(21)00005-0
- Sci Rep, 2021 11(1):6270
- AAPS J, 2021 23(5):101
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Pigment Cell Melanoma Res, 2021 10.1111/pcmr.13014
- Front Neurosci, 2021 15:743207
- Hum Cell, 2021 34(6):1911-1918
- Front Physiol, 2021 12:712583
- Brain Res Bull, 2021 172:79-88
- PLoS One, 2021 16(4):e0244771
- Naunyn Schmiedebergs Arch Pharmacol, 2021 10.1007/s00210-021-02140-z
- Genes (Basel), 2021 12(2)260
- Mol Med Rep, 2021 23(2)143
- Reprod Sci, 2021 10.1007/s43032-021-00533-2
- Neurosci Lett, 2021 764:136241
- Medicina (Kaunas), 2021 57(5)456
- Adv Sci (Weinh), 2020 7(21):2001364
- Nucleic Acids Res, 2020 10.1093/nar/gkaa088
- Acta Pharm Sin B, 2020 10(4):615-627
- Theranostics, 2020 1;10(3):1433-1453
- J Immunother Cancer, 2020 8(2)e001037
- J Immunother Cancer, 2020 8(1)
- Genes Dev, 2020 34(5-6):428-445
- PLoS Biol, 2020 18(12):e3000941
- PLoS Biol, 2020 18(11):e3000981
- J Neuroinflammation, 2020 22;17(1):125
- Br J Cancer, 2020 10.1038/s41416-020-01191-y
- Br J Cancer, 2020 27
- Oncogene, 2020 10.1038/s41388-020-01394-w
- Oncogene, 2020 10.1038/s41388-020-01408-7
- EMBO Rep, 2020 21:e50162
- PLoS Pathog, 2020 16;16(3):e1008341
- Biomater Sci, 2020 10.1039/d0bm00119h
- Cancer, 2020 1;126(9):2024-2033
- Life Sci, 2020 248:117469
- Chin Med J (Engl), 2020 5;133(11):1304-1311
- Colloids Surf B Biointerfaces, 2020 188:110753
- Cancer Cell Int, 2020 19;20:58
- Biochem Pharmacol, 2020 3;178:114067
- Cancer Sci, 2020 111(12):4429-4441
- Cancer Sci, 2020 111(7):2374-2384
- Mol Cancer Ther, 2020 19(2):637-649
- Clin Epigenetics, 2020 12(1):13
- Front Cell Dev Biol, 2020 17;8:158
- J Virol, 2020 4;94(10) pii: e01923-19
- ACS Infect Dis, 2020 29
- Cancers (Basel), 2020 12(11)E3172
- Mol Cancer Res, 2020 18(7):1004-1017
- Viruses, 2020 12(10)E1067
- Front Oncol, 2020 10:296
- Sci Rep, 2020 10(1):12864
- Pharmaceuticals (Basel), 2020 13(11)E345
- Andrology, 2020 10.1111/andr.12922
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Cell Cycle, 2020 1-16
- BMC Microbiol, 2020 20(1):28
- Pharm Biol, 2020 58(1):231-238
- PLoS One, 2020 15;15(5):e0232985
- Cancer Manag Res, 2020 12:4429-4439
- HIV Med, 2020 21(11):747-757
- Oncol Lett, 2020 19(1):460-468
- Am J Transl Res, 2020 12(10):6187-6203
- Sci Adv, 2020 6(29):eaba1941
- Sci Adv, 2020 6(33):eaba6617
- J Med Invest, 2020 67(3.4):343-350
- Nat Commun, 2019 10(1):4192
- Acta Pharm Sin B, 2019 9(5):937-951
- Mol Ther, 2019 27(5):1039-1050
- Theranostics, 2019 9(2):540-553
- Cancer Res, 2019 79(7):1658-1670
- J Pineal Res, 2019 66(3):e12556
- Haematologica, 2019 10.3324/haematol.2018.211110
- Haematologica, 2019 104(11):2225-2240
- Pharmacol Res, 2019 139:524-534
- Pharmacol Res, 2019 146:104281
- Cell Rep, 2019 27(11):3331-3344
- Cell Commun Signal, 2019 17(1):4
- Acta Pharmacol Sin, 2019 40(5):677-688
- Elife, 2019 8
- Front Immunol, 2019 9:3162
- Apoptosis, 2019 24(5-6):404-413
- Thyroid, 2019 29(5):726-734
- Mol Oncol, 2019 10.1002/1878-0261.12607
- Int J Cancer, 2019 145(9):2496-2508
- Cells, 2019 8(12)
- Oncologist, 2019 24(8):e740-e748
- Mol Cancer Ther, 2019 18(5):900-908
- Clin Epigenetics, 2019 11(1):85
- Int J Mol Sci, 2019 20(13)
- Front Cell Neurosci, 2019 13:468
- Cancers (Basel), 2019 11(5)E645
- Cancers (Basel), 2019 11(4)
- Gene Ther, 2019 26(3-4):75-85
- Chem Biol Interact, 2019 306:54-61
- Mol Pharm, 2019 16(9):3904-3915
- J Biol Chem, 2019 294(12):4437-4449
- Int J Neuropsychopharmacol, 2019 22(8):523-527
- J Neurochem, 2019 10.1111/jnc.14935
- Sci Rep, 2019 9(1):1897
- Oncol Rep, 2019 41(2):1007-1018
- ACS Omega, 2019 4(22):19895-19904
- Bone, 2019 125:112-121
- Cancer Med, 2019 8(14):6383-6392
- Stem Cells Dev, 2019 28(7):438-453
- AIDS, 2019 33(2):199-209
- PLoS One, 2019 14(6):e0218382
- Epigenetics, 2019 10.1080/15592294.2019.1656155
- Epigenetics, 2019 14(8):791-803
- Epigenetics, 2019 10.1080/15592294.2019.1656156
- Cancer Biol Ther, 2019
- Hum Mol Genet, 2019 10.1093/hmg/ddz254
- Front Neurol, 2019 10:893
- Adipocyte, 2019 8(1):292-303
- Tuberculosis (Edinb), 2019 118:101861
- Nucl Med Biol, 2019 74-75:1-11
- Neoplasma, 2019 66(1):20-27
- NMR Biomed, 2019 32(2):e4044
- Exp Ther Med, 2019 17(6):4547-4553
- Exp Hematol, 2019 72:60-71
- Res Vet Sci, 2019 126:207-212
- Alcohol, 2019 78:79-87
- Anticancer Res, 2019 39(7):3579-3584
- Medicina (Kaunas), 2019 55(2)
- Chin J Dent Res, 2019 22(4):221-227
- Nat Commun, 2018 13;9(1):2720
- J Med Virol, 2018 90(9):1478-1485
- Clin Cancer Res, 2018 24(16):3941-3954
- J Exp Clin Cancer Res, 2018 37(1):153
- Cancer Res, 2018 78(10):2705-2720
- Cancer Res, 2018 78(20):5731-5740
- J Control Release, 2018 275:117-128
- Haematologica, 2018 103(4):679-687
- Cancer Lett, 2018 432:121-131
- Acta Biomater, 2018 71:261-270
- JCI Insight, 2018 3(4)95824
- JCI Insight, 2018 3(22)125568
- Biol Sex Differ, 2018 9(1):12
- Sci Signal, 2018 11(557)
- Oncoimmunology, 2018
- PLoS Pathog, 2018 14(6):e1007061
- Cancer Sci, 2018 109(8):2520-2531
- Mol Cancer Ther, 2018 17(12):2767-2779
- Front Pharmacol, 2018 9:509
- J Virol, 2018 92(10)
- J Virol, 2018 92(6)
- J Cell Mol Med, 2018 22(5):2600-2611
- Front Microbiol, 2018 9:2022
- Sci Rep, 2018 8(1):3521
- Sci Rep, 2018 8(1):3875
- Oncol Rep, 2018 39(1):264-270
- J Cell Biochem, 2018 119(5):4193-4204
- BMC Cancer, 2018 18(1):466
- Exp Cell Res, 2018 371(1):231-237
- Cell Biochem Funct, 2018 36(8):398-407
- Ann Hematol, 2018 97(5):839-849
- AAPS PharmSciTech, 2018 19(2):634-647
- Retrovirology, 2018 15(1):36
- Alcohol Clin Exp Res, 2018 42(11):2160-2171
- Biochem Biophys Res Commun, 2018 498(3):481-486
- Oncol Lett, 2018 15(5):6107-6114
- Sci Adv, 2018 4(9):eaar4666
- Curr Protoc Pharmacol, 2018 81(1):e41
- Nat Struct Mol Biol, 2017 24(1):47-54
- Clin Cancer Res, 2017 23(12):3084-3096
- Clin Cancer Res, 2017 23(12):3139-3149
- Proc Natl Acad Sci USA, 2017
- Proc Natl Acad Sci U S A, 2017 114-14:3648-3653
- Haematologica, 2017 102(4):736-745
- Cell Death Dis, 2017 8(1):e2570
- Cell Death Dis, 2017
- Cell Chem Biol, 2017 24(11):1356-1367.e8
- Oncogene, 2017 36(34):4859-4874
- JCI Insight, 2017 2(1):e85811
- JCI Insight, 2017 2(6):e90196
- Oncogene, 2017 36(12):1707-1720
- Br J Pharmacol, 2017 174(20):3608-3622
- Sci Signal, 2017 10(508)eaan8355
- Eur J Med Chem, 2017 127:531-553
- Eur J Med Chem, 2017 141:596-602
- Cancer Sci, 2017 108(7):1485-1492
- Mol Ther Oncolytics, 2017
- Int J Mol Sci, 2017 18(5)
- Oncotarget, 2017 8(11):17995-18009
- Oncotarget, 2017 8(28):45687-45697
- Oncotarget, 2017 9(1):512-523
- Oncotarget, 2017 8(31):51429-51446
- Oncotarget, 2017 8(45):78480-78495
- Oncotarget, 2017
- Oncotarget, 2017
- Oncotarget, 2017 10.18632/oncotarget.15017
- Oncotarget, 2017 8(44):77254-77267
- Oncotarget, 2017 8(61):103797-103814
- J Biol Chem, 2017 292(12):5043-5054
- Cancer Res Treat, 2017 49(2):374-386
- Sci Rep, 2017 7(1):2290
- Sci Rep, 2017 7(1):11547
- Sci Rep, 2017 7(1):10921
- Int J Cell Biol, 2017 2017:6169310
- Cancer Med, 2017 6(11):2673-2685
- Pharm Res, 2017 34(3):668-679
- Nucleus, 2017 8(5):515-533
- PLoS One, 2017 12(10):e0186620
- Mol Immunol, 2017 87:76-85
- J Pharmacol Exp Ther, 2017 363(2):211-220
- CPT Pharmacometrics Syst Pharmacol, 2017 6(11):756-764
- Bioorg Med Chem, 2017 25(7):2105-2132
- Pulm Pharmacol Ther, 2017 44:88-95
- Biochem Biophys Res Commun, 2017 491(4):939-945
- Am J Surg, 2017 213(4):645-651
- Connect Tissue Res, 2017 58(1):64-75
- Nat Commun, 2016 7:11363
- Cell Death Differ, 2016 23(8):1312-21
- Cancer Res, 2016 76(8):2376-83
- Cancer Res, 2016 76(23):7001-7011
- Drug Discov Today, 2016 21(9):1553-1560
- J Med Chem, 2016 59(4):1613-33
- Oncoimmunology, 2016
- Mol Cell Proteomics, 2016 15(6):2076-92
- Int J Cancer, 2016 139(1):194-204
- mBio, 2016 7(6)
- Am J Pathol, 2016 186(10):2701-8
- Biochem Pharmacol, 2016 102:130-140
- Mol Cancer Ther, 2016 15(10):2432-2441
- Mol Cancer Ther, 2016 15(5):830-41
- Mol Cancer Ther, 2016 15(6):1364-75
- Oncotarget, 2016 7(42):68360-68370
- Oncotarget, 2016 8(62):104733-104744
- Oncotarget, 2016 7(7):7390-402
- Oncotarget, 2016
- Oncotarget, 2016 7(36):58142-58147
- Oncotarget, 2016 7(6):6727-47
- Int J Oncol, 2016 49(6):2453-2463
- Inflammation, 2016 39(1):39-46
- Am J Physiol Heart Circ Physiol, 2016 311(5):H1139-H1149
- J Biol Chem, 2016 291(19):10131-47
- Neuropharmacology, 2016 107:111-121
- Sci Rep, 2016 6:38219
- Sci Rep, 2016 6:21678
- Anal Bioanal Chem, 2016 408(13):3547-53
- Neurochem Int, 2016 96:24-31
- ACS Chem Biol, 2016 11(10):2685-2692
- Onco Targets Ther, 2016 9:6843-6855
- Endocr Relat Cancer, 2016 23(7):521-33
- BMC Cancer, 2016 16:667
- PLoS One, 2016 11(8):e0160826
- PLoS One, 2016 11(1):e0145985
- Biol Chem, 2016
- Cancer Biol Ther, 2016 17(1):27-35
- J Hum Genet, 2016 10.1038/jhg.2016.61
- Med Oncol, 2016 33(2):11
- Asian Pac J Trop Med, 2016 9(6):572-6
- Leuk Lymphoma, 2016 57(3):692-9
- Genet Mol Res, 2016 15(4)
- Nat Commun, 2015 6:7888
- Nat Commun, 2015 3;6:10091
- Blood Cancer J, 2015 5:e312
- Cell Death Differ, 2015 22(8):1328-40
- Clin Cancer Res, 2015 21(7):1628-38
- Clin Cancer Res, 2015 10.1158/1078-0432.CCR-14-2701
- Cancer Res, 2015
- EMBO Mol Med, 2015 10.15252/emmm.201404396
- EBioMedicine, 2015 3:108-121
- EMBO Mol Med, 2015 10.15252/emmm.201404580
- Circ Heart Fail, 2015 8(6):1094-104
- Cancer Lett, 2015 356(2 Pt B):828-36
- Cancer Lett, 2015 366(1):32-43
- Cell Death Dis, 2015 6:e1692
- Cell Death Dis, 2015 6:e1657
- Breast Cancer Res, 2015 17:33
- Apoptosis, 2015 20(7):975-85
- Acta Neuropathol Commun, 2015 3(1):22
- Cell Death Discov, 2015 115012
- Br J Haematol, 2015 168(3):371-83
- Biochem Pharmacol, 2015 94(2):79-90
- Oncotarget, 2015 6(18):15814-27
- Oncotarget, 2015 6(15):13757-71
- Oncotarget, 2015 6(28):25801-14
- Am J Cancer Res, 2015 5(4):1337-52
- J Neurosci, 2015 35(33):11729-42
- J Biol Chem, 2015 290(8):5028-40
- J Biol Chem, 2015 290(39):23725-37
- Front Mol Neurosci, 2015 8:52
- J Biol Chem, 2015 290(3):1829-36
- Neuropharmacology, 2015 99:67-78
- J Biotechnol, 2015 10.1016/j.jbiotec.2015.02.029
- ACS Chem Biol, 2015 10(10):2316-24
- Endocr Relat Cancer, 2015 22(5):777-92
- BMC Cancer, 2015 15:343
- BMC Cancer, 2015 15(1):273
- PLoS One, 2015 10(6):e0130339
- PLoS One, 2015 10(10):e0139740
- PLoS One, 2015 10(8):e0134825
- Epigenetics, 2015 10.1080/15592294.2015.1039216
- PLoS One, 2015 10(12):e0143897
- FEBS Lett, 2015 589(10):1080-8
- Mol Med Rep, 2015 12(3):4291-4297
- J Biomol Screen, 2015 20(10):1286-93
- Mol Vis, 2015 21:502-14
- Genes Cancer, 2015 6(3-4):169-81
- Sci Transl Med, 2014 6(256):256ra135
- Nat Commun, 2014 5:3361
- Acta Neuropathol, 2014 128(2):291-303
- Clin Cancer Res, 2014 10.1158/1078-0432.CCR-14-0384
- Cancer Lett, 2014 351(1):50-8
- Cell Death Dis, 2014 5:e1134
- Cell Death Dis, 2014 5:e1177
- Oncogene, 2014 33(25):3307-15
- Diabetes, 2014 63(9):2924-34
- PLoS Pathog, 2014 10(4):e1004071
- Int J Cancer, 2014 135(7):1721-32
- Cancer Cell Int, 2014 14(1):112
- Mol Cancer Ther, 2014 13(12):2784-92
- J Mol Biol, 2014 426(20):3442-53
- Oncotarget, 2014 5(14):5637-50
- Oncotarget, 2014 5(15):5965-77
- Mol Cell Biol, 2014 34(7):1280-9
- J Biol Chem, 2014 289(14):9918-25
- Hum Gene Ther, 2014 25(7):599-608
- J Alzheimers Dis, 2014 41(4):1193-205
- BMC Cancer, 2014 14(1):373
- PLoS One, 2014 9(11):e113341
- Cytometry A, 2014 85(1):78-87
- Virology, 2014 462-463:328-39
- Cancer Biol Ther, 2014 15(5):578-85
- Cancer Biol Ther, 2014 15(3):305-16
- Hum Mol Genet, 2014 23(10):2651-64
- Human Molecular Genetics, 2014 -2651–2664
- FEBS Lett, 2014 588(9):1571-9
- Mol Med Rep, 2014 10(5):2729-35
- Oncol Lett, 2014 7(5):1673-1678
- Head Neck, 2014 10.1002/hed.23822.
- Pharmacol Res Perspect, 2014 2(3):e00043
- Proteomics Clin Appl, 2014 8(11-12):924-31
- Curr Pharm Desigh, 2014 20(11):1874-80
- Pharmacology Research Perspectives, 2014 10.1002/prp2.43
- Methods Mol Biol, 2014 1156:431-43
- Nat Struct Mol Biol, 2013 20(3):317-25
- Cancer Res, 2013 73(8):2428-34
- Proc Natl Acad Sci USA, 2013 111(3):E364-73
- PLoS Biol, 2013 12(1):e1001758
- Cell Death Dis, 2013 4:e733
- Cell Death Dis, 2013 4:e655
- Cell Death Dis, 2013 4:e951
- Cell Rep, 2013 5(6):1679-89
- Oncogene, 2013 33(33):4265-72
- Oncogene, 2013 32(10):1316-29
- Neuropsychopharmacology, 2013 38(9):1674-84
- Apoptosis, 2013 18(11):1348-1362
- Br J Haematol, 2013 160(2):188-98
- Int J Cancer, 2013 132(9):2200-8
- Front Pharmacol, 2013 4:44
- Skelet Muscle, 2013 3(1):27
- J Biol Chem, 2013 288(35):25593-602
- J Biol Chem, 2013 288(20):14400-7
- Mol Carcinog, 2013 52(3):218-28
- Cell Cycle, 2013 12(13):2073-83
- PLoS Comput Biol, 2013 9(2):e1002887
- J Thromb Thrombolysis, 2013 35(2):185-92
- AIDS, 2013 27(18):2853-62
- PLoS One, 2013 8(6):e66130
- PLoS One, 2013 8(1):e53766
- Genes Brain Behav, 2013 13(1):69-86
- J Exp Med, 2012 209(1):35-50
- Cell Death Differ, 2012 19(12):2029-39
- Cell Death Differ, 2012 19(8):1317-27
- Clin Cancer Res, 2012 18(14):3822-33
- Clin Cancer Res, 2012 18(2):408-16
- Cancer Res, 2012 72(9):2251-61
- Eur J Cancer, 2012 48(7):1096-107
- Diabetologia, 2012 55(9):2421-31
- J Leukoc Biol, 2012 91(5):701-9
- J Biol Chem, 2012 287(43):36609
- FASEB J, 2012 26(7):3032-41
- J Neurochem, 2012 123 Suppl 2:108-15
- Mol Carcinog, 2012 52(6):459-74
- Oncol Rep, 2012 28(1):105-10
- PLoS One, 2012 7(7):e40684
- Pharm Res, 2012 29(7):1960-76
- PLoS One, 2012 7(9):e44265
- PLoS One, 2012 7(12):e52335
- PLoS One, 2012 7(12):e52753
- Invest New Drugs, 2012 30(2):541-7
- Biochem Biophys Res Co, 2012 420(2):325-30
- Chronobiol Int, 2012 29(8):982-93
- Pediatr Surg Int, 2012 28(6):579-89
- Protein Expr Purif, 2012 86(1):45-52
- Brain, 2011 134(Pt 8):2408-21
- Clin Cancer Res, 2011 17(9):2819-29
- Clin Cancer Res, 2011 17(16):5311-21
- Genes Dev, 2011 25(24):2610-8
- J Transl Med, 2011 9:37
- Mol Med, 2011 17(5-6):466-72
- J Neurosci, 2011 31(11):3990-9
- PLoS One, 2011 6(6):e21382
- PLoS One, 2011 6(7):e22739
- Retrovirology, 2011 2(3):411-23
- BMC Neurosci, 2011 12:50
- Sci Signal, 2010 3(146):ra80
- Exp Dermatol, 2010 19(12):1096-102
- J Pharmacol Exp Ther, 2010 86(16):8765-72
化学信息&溶解度
分子量 | 264.3 |
分子式 | C14H20N2O3 |
CAS号 | 149647-78-9 |
Smiles | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 52 mg/mL ( 196.74 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 6.5 mg/mL Water : Insoluble DMSO : 53 mg/mL ( 200.52 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 18 mg/mL Water : Insoluble DMSO : 53 mg/mL ( 200.52 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 2 mg/mL Water : Insoluble DMSO : 53 mg/mL ( 200.52 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 2 mg/mL Water : Insoluble DMSO : 53 mg/mL ( 200.52 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 4 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
Corn oil
浓度:2.5mg/ml
(9.46mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。